Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HUTCHMED (China) (HCM) Notes Payables (2016 - 2025)

Historic Notes Payables for HUTCHMED (China) (HCM) over the last 9 years, with Q2 2025 value amounting to $25.6 million.

  • HUTCHMED (China)'s Notes Payables fell 326.81% to $25.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $25.6 million, marking a year-over-year decrease of 326.81%. This contributed to the annual value of $10.6 billion for FY2024, which is 451.04% up from last year.
  • Latest data reveals that HUTCHMED (China) reported Notes Payables of $25.6 million as of Q2 2025, which was down 326.81% from $10.7 billion recorded in Q4 2024.
  • HUTCHMED (China)'s Notes Payables' 5-year high stood at $10.7 billion during Q4 2024, with a 5-year trough of $418000.0 in Q2 2022.
  • For the 5-year period, HUTCHMED (China)'s Notes Payables averaged around $3.0 billion, with its median value being $26.5 million (2024).
  • In the last 5 years, HUTCHMED (China)'s Notes Payables plummeted by 9844.51% in 2022 and then surged by 43865579.4% in 2023.
  • Quarter analysis of 5 years shows HUTCHMED (China)'s Notes Payables stood at $26.9 million in 2021, then crashed by 91.39% to $2.3 million in 2022, then surged by 438655.79% to $10.2 billion in 2023, then grew by 4.89% to $10.7 billion in 2024, then crashed by 99.76% to $25.6 million in 2025.
  • Its Notes Payables stands at $25.6 million for Q2 2025, versus $10.7 billion for Q4 2024 and $26.5 million for Q2 2024.